Breaking News, Promotions & Moves

Oculis Names Dr. Snehal Shah as President of R&D

Shah joins from Iveric Bio where he served as Chief Regulatory & Product Strategy Officer.

Author Image

By: Charlie Sternberg

Associate Editor

Oculis Holding AG, a global biopharmaceutical company, has appointed Dr. Snehal Shah, an executive leader with over two decades of research & development (R&D) and regulatory experience, to the role of President of R&D.   Shah will be responsible for leading research and development strategies, and working towards achieving market authorizations by directing global regulatory activities required for future New Drug Application (NDA) submissions to the U.S. Food and Drug Administrat...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters